RNS Number:4925O
Alizyme PLC
08 August 2003


For Immediate Release                                            8 August 2003



DIRECTOR SHARE OPTIONS


Cambridge UK, 8 August 2003: Alizyme plc (LSE:AZM) today announces that the
following directors have been awarded share options under the following scheme:



The Alizyme plc 2001 Unapproved Executive Share Option Scheme (the"Scheme"):
                    Grant      Exercise Price    Date of Grant    Valid Until

Dr Richard Palmer  731,817           49.5p      8 August 2003    7 August 2013

Mr Tim McCarthy    477,271           49.5p      8 August 2003    7 August 2013


In accordance with the rules of the Scheme, the Exercise Price is calculated as
the average closing price over the preceding five dealing days and the exercise
of these options is subject to the satisfaction of objective performance-related
conditions and a three year vesting period. In view of both Directors'
contribution to the Company over the period since their last share option award,
the Remuneration Committee has determined the circumstances to be exceptional
and has therefore used its discretion under the rules of the Scheme to exceed
the individual annual limit on the number of options available for grant by 50%
for both Dr Palmer and Mr McCarthy.






Commenting on the award, John Gordon, Chairman of the Remuneration Committee
said:

"Following the Company's announcements today on its agreement with Takeda and
its interim results to 30 June 2003, the Remuneration Committee believe an
exceptional award of share options to be appropriate for both Dr Richard Palmer
and Mr Tim McCarthy, who have made an outstanding contribution to Alizyme's
recent progress and will continue to play an important role in the Company's
future development."






For further information, please contact:

Dr Richard Palmer, Chief Executive Officer
Mr Tim McCarthy, Finance Director
ALIZYME plc                                         Tel No: + 44 (0)1223 896 000

Lisa Baderoon

BUCHANAN COMMUNICATIONS                             Tel No: + 44 (0)20 7466 5000


Further information on Alizyme can be found on the Company's website:
www.alizyme.com








                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RDSNKFKBNBKDPFK